Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by retiredcopon Jun 02, 2021 5:16pm
128 Views
Post# 33314128

RE:RE:RE:FDA decision will have waterfall effect on other companies

RE:RE:RE:FDA decision will have waterfall effect on other companies
DavidKingCanada wrote: Am also curious as to what RC as to say, hoping for Great News!


So far what I have been hearing as speculation on share price for PMN... I think if its a approval for Biogen up we are up 2-5 cents ... if its a non approval for biogen its 3-5 cents in the opposite direction. I think we already see that regardless of what happens to Biogen, the new investors have indicated they are taking pmn310 to clinicals and I would expect that there will be a third party that will be coming on board to cover the remaining money needed for the clinicals... or the other scenerio ... we get suddenly get alot of money coming into PMN from serology test(s) , small deals with PD or ALS in the next few months and we dont need the 3rd party. The big jump in shares will be a result of our progress and accomplishments... that of course is my opinion and as a disclosure I have a terrible track record these past 15 years !!!!!     
<< Previous
Bullboard Posts
Next >>